Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signed Informed Consent~* Able to swallow an oral medication~* Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram~* Adequate kidney and liver function~* Adequate bone marrow function~* Tumor tissue available for testing~* Prior adjuvant or neoadjuvant therapy is permitted with an anthracycline or anthracenedione-containing regimen however, subjects must have had cumulative doses of less than 360 mg/m2 of doxorubicin, 720 mg/m2 of epirubicin, or 72 mg/m2 of mitoxantrone~* No Her2/neu overexpression in tumor tissue tested or status unknown if tissue has never been tested~Exclusion criteria:~* Prior treatment regimens for advanced or metastatic breast cancer.~* Pregnant or lactating~* Conditions that would effect the absorption of an oral drug~* Active infection~* Brain metastases~* Treatment with EGFR (Endothelial Growth Factor Receptor) inhibitor.~* Known hypersensitivity to Taxol or excipients of Taxol~* Peripheral neuropathy of Grade 2 or greater is not permitted~* Severe Cardiovascular disease or cardiac disease requiring a device.~* Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
- Arm 2 (Type: PLACEBO_COMPARATOR): Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).